ERBB2 and neoplasm: A retrospective analysis of the PETACC-8 trial (n = 1795) found that HER-2 amplification and mutation were associated with shorter disease-free survival (DFS) (95% confidence interval [CI] 1.02-2.36, P = 0.04) and worse overall survival (OS) (95% CI 0.99-2.5, P = 0.05) Even after adjusting for other prognostic factors such as RAS mutations, grading, tumor location, pT and pN status, bowel obstruction or perforation, lymphatic or venous invasion, the prognostic impact still persisted (8).